Akebia Therapeutics, Inc. (AKBA) vs Lifecore Biomedical, Inc. (LFCR)
Over the past 10 years, AKBA lagged LFCR — -20.53% vs -6.99% annualized total return (price plus dividends).
A side-by-side comparison of Akebia Therapeutics, Inc. and Lifecore Biomedical, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
Total return — AKBA vs LFCR
growth of $100 · dividends reinvested · last 10yMetrics side by side
Did AKBA beat LFCR?
Over the past 10 years, AKBA lagged LFCR — -20.53% vs -6.99% annualized total return (price plus dividends).
Total return (annualized)
| Metric | AKBA | LFCR |
|---|---|---|
| Total return (1Y) | -67.65% | -6.56% |
| Total return CAGR (3Y) | -4.03% | -1.05% |
| Total return CAGR (5Y) | -20.07% | -7.12% |
| Total return CAGR (10Y) | -20.53% | -6.99% |
LFCR is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has AKBA beaten LFCR?
- Over the past 10 years, AKBA lagged LFCR — -20.53% vs -6.99% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.